Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SER Stock Forecast 2025-2026
$6.09
Current Price
$56.02M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SER Price Targets
+80.6%
To High Target of $11.00
+80.6%
To Median Target of $11.00
+80.6%
To Low Target of $11.00
SER Price Momentum
+8.2%
1 Week Change
+16.0%
1 Month Change
-28.4%
1 Year Change
+21.6%
Year-to-Date Change
-58.2%
From 52W High of $14.57
+59.8%
From 52W Low of $3.81
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Serina (SER) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SER and similar high-potential opportunities.
Latest SER Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, SER has a bullish consensus with a median price target of $11.00 (ranging from $11.00 to $11.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $6.09, the median forecast implies a 80.6% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Justin Walsh at Jones Trading, projecting a 80.6% upside. Conversely, the most conservative target is provided by Justin Walsh at Jones Trading, suggesting a 80.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SER Analyst Ratings
1
Buy
0
Hold
0
Sell
SER Price Target Range
Low
$11.00
Average
$11.00
High
$11.00
Current: $6.09
Latest SER Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SER.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 11, 2025 | Jones Trading | Justin Walsh | Buy | Initiates | $11.00 |
Serina Therapeutics Inc. (SER) Competitors
The following stocks are similar to Serina based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SER
Serina Therapeutics
mkt cap
56.02M
Serina Therapeutics Inc. (SER) Financial Data
Serina Therapeutics Inc. has a market capitalization of $56.02M with a P/E ratio of 1.7x. The company generates $56,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of +29,092.9% and return on equity of -485.4%.
Valuation Metrics
Market Cap
$56.02M
Enterprise Value
$53.72M
P/E Ratio
1.7x
PEG Ratio
0.1x
Price/Sales
1,000.3x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
+29,092.9%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+6.1%
Current Ratio
2.4x
Debt/Equity
90.7x
ROE
-485.4%
ROA
-124.0%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Serina Therapeutics Inc. (SER) Business Model
About Serina Therapeutics Inc.
What They Do
Develops polymer-based therapeutics for medical challenges.
Business Model
Serina Therapeutics Inc. generates revenue through the development and commercialization of its proprietary polyoxazoline (POZ) polymer technology, which enhances drug delivery and efficacy. By targeting significant medical issues, particularly in neurological diseases, cancer, and autoimmune conditions, the company aims to create tailored therapeutic solutions that meet the needs of patients and healthcare providers.
Additional Information
The company's innovative approach positions it strategically in the biopharmaceutical sector, focusing on precision medicine. With the potential to improve pharmacokinetics and safety profiles, Serina Therapeutics holds promise for addressing unmet medical needs and impacting the future of drug delivery.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
12
CEO
Mr. Steven A. Ledger
Country
United States
IPO Year
2024
Website
serinatherapeutics.comSerina Therapeutics Inc. (SER) Latest News & Analysis
Latest News
Quick Summary
Serina Therapeutics granted 15,000 stock options to two new employees on March 20, 2025, with an exercise price at the closing stock price on that date. Options vest over three years.
Why It Matters
Serina Therapeutics' stock options for new employees align their interests with shareholders, potentially enhancing company performance and stock value, which is critical for investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
10 days ago
Quick Summary
Serina Therapeutics, Inc. (NYSE American: SER) reported its Q1 2025 financial results and recent business developments, focusing on its POZ Platform™ drug optimization technology.
Why It Matters
Serina Therapeutics' Q1 financial results and updates on its POZ Platform™ may indicate its growth potential, impacting stock valuation and investor confidence in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Serina Therapeutics (NYSE American: SER) will have CEO Steve Ledger present at the Virtual CNS Day on April 29, 2025, at 12:00 p.m. EDT, showcasing its POZ Platform™ technology.
Why It Matters
CEO presentations can indicate company momentum and strategic direction. Serina's focus on drug optimization may attract interest and impact stock performance in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Serina Therapeutics (NYSE American: SER) will present new data on its POZ Platform™ at the LNP Formulation Summit on April 15, focusing on solutions for anti-PEG antibodies in mRNA therapies.
Why It Matters
Serina's presentation on its POZ-lipid technology could enhance mRNA therapeutic efficacy, potentially boosting the company's stock value and attracting investor interest in its innovations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Serina Therapeutics closed a $5M financing from strategic shareholders to advance SER-252 for Advanced Parkinson's disease, with a Phase 1 trial set to begin in Q4 2025.
Why It Matters
Serina Therapeutics secured $5 million for advancing SER-252, a key candidate for Parkinson's disease, indicating potential growth and innovation in its pipeline, influencing investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
1 month ago
Quick Summary
Serina Therapeutics (NYSE American: SER) will present its POZ Platform™ at the Jones Healthcare and Technology Innovation Conference in Las Vegas on April 9, 2025, at 3:00 p.m. PDT.
Why It Matters
CEO presentations at industry conferences can boost investor confidence and interest in a company's innovations, potentially impacting stock price and market perception of its growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SER Stock
What is Serina Therapeutics Inc.'s (SER) stock forecast for 2025?
Based on our analysis of 1 Wall Street analysts, Serina Therapeutics Inc. (SER) has a median price target of $11.00. The highest price target is $11.00 and the lowest is $11.00.
Is SER stock a good investment in 2025?
According to current analyst ratings, SER has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.09. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SER stock?
Wall Street analysts predict SER stock could reach $11.00 in the next 12 months. This represents a 80.6% increase from the current price of $6.09. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Serina Therapeutics Inc.'s business model?
Serina Therapeutics Inc. generates revenue through the development and commercialization of its proprietary polyoxazoline (POZ) polymer technology, which enhances drug delivery and efficacy. By targeting significant medical issues, particularly in neurological diseases, cancer, and autoimmune conditions, the company aims to create tailored therapeutic solutions that meet the needs of patients and healthcare providers.
What is the highest forecasted price for SER Serina Therapeutics Inc.?
The highest price target for SER is $11.00 from Justin Walsh at Jones Trading, which represents a 80.6% increase from the current price of $6.09.
What is the lowest forecasted price for SER Serina Therapeutics Inc.?
The lowest price target for SER is $11.00 from Justin Walsh at Jones Trading, which represents a 80.6% increase from the current price of $6.09.
What is the overall SER consensus from analysts for Serina Therapeutics Inc.?
The overall analyst consensus for SER is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $11.00.
How accurate are SER stock price projections?
Stock price projections, including those for Serina Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 18, 2025 10:26 AM UTC